Press Release

Opthea – $128 Million IPO

Largest IPO by a development-stage Australian life sciences company
November 3, 2020

Singapore – November 3, 2020 – Cooley advised Opthea, a biopharmaceutical company focused on therapies for progressive retinal diseases, on its $128 million initial public offering of 8,563,300 American Depository Shares. The underwriters have the option to purchase up to an additional 1,425,000 shares. Partners Ferish Patel, Div Gupta, John McKenna and Brent Siler led the global Cooley team advising Opthea.

Opthea’s Nadsaq debut marks the largest IPO conducted by a development-stage Australian life sciences company, as well as the largest Australian biotech capital raise in a secondary Nasdaq IPO.

Citigroup Global Markets and SVB Leerink acted as joint book-running managers for the offering. Oppenheimer & Co. and Truist Securities acted as lead managers. 

Opthea, whose securities now trade on the Nasdaq Global Select Market under the symbol “OPT,” is developing a novel therapy to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration and diabetic macular edema. 

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. 

Cooley has 1,100+ lawyers across 16 offices in the United States, Asia and Europe.